R7 (drug)
| Clinical data | |
|---|---|
| Legal status | |
| Routes of administration |
Oral |
R7 is a prodrug of 7,8-dihydroxyflavone (7,8-DHF) with significantly improved potency and pharmacokinetics (namely oral bioavailability) that is currently in preclinical development for the treatment of Alzheimer's disease.[1] As a prodrug of 7,8-DHF, R7 is a selective agonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF).[1] 7,8-DHF shows robust efficacy in a variety of animal models of Alzheimer's disease as well as other conditions, making R7 a highly promising potential therapeutic agent.[1] The chemical structure of the compound has yet to be published.[1]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- Pages with reference errors
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Antidementia agents
- Flavones
- Neuroprotective agents
- Nootropics
- Prodrugs
- TrkB agonists
- Nervous system drug stubs
